Business Wire

WA-KYMETA

Share
Kymeta Launches KĀLO™ Trek Across America

Redmond-based Kymeta—the communications company making good on the promise of global mobile connectivity—set out on a two-week trek across America in its connected Toyota RAV4 to provide a rigorous, real-world proving ground for its widely anticipated KĀLO™ internet service. KĀLO services will deliver a new mobile satellite internet service that will make mobile high-throughput internet access available and easy to buy. The KĀLO Trek Across America will begin in Washington, D.C. and wind through the country, covering over 7,000 miles, and culminating in a homecoming event at the Kymeta campus in Washington state on November 27.

Powered by the IntelsatOne® Flex network, Kymeta KĀLO services will provide high-bandwidth mobile satellite internet access to industries that require connectivity on the move like military, news reporting, first responders, construction, trains, buses and more. KĀLO services, when paired with Kymeta™ KyWay™ terminals and mTennau7 ASMs, will connect places and fixed and mobile platforms that have traditionally had limited or no connectivity at all.

“Kymeta is taking its connected car across the country to put the network through the paces,” said Dushyant Sukhija, SVP and General Manager, KĀLO Business Unit, Kymeta. “When launched, KĀLO mobile internet services will mark a revolutionary change in the way satellite services are purchased and supplied, making it as simple as purchasing a cell phone plan. The launch of Kymeta KĀLO services will usher in changes in the way businesses get work done: on the move, from everyday vehicles, in even the most difficult to reach industries and areas of the world.”

The KĀLO Trek Across America tells another important story: the possibility of a truly connected car is now a reality. Kymeta’s Toyota RAV4 will remain connected throughout its U.S. journey, conducting live streams and updates from the road. “As innovations in satellite connectivity come to market, such as our Intelsat EpicNG high-throughput satellites, we are unlocking new applications. Industries recognize that connected cars and other vehicles will enable new services and opportunities for increased efficiency; traditional networks can’t support that growth today,” said Mark Rasmussen, VP and General Manager, Mobility, Intelsat. “Leveraging our global IntelsatOne Flex network, our partnership with Kymeta will bring KĀLO internet services to every corner of the U.S., and eventually every region of the world. This plan aligns to our goal: make connectivity accessible to everyone, everything, everywhere, at any time. Kymeta KĀLO services are proof that connectivity can reach every industry, large and small, and be used for any application, no matter where you are, especially while you’re on the move.”

For a map of the KĀLO Trek Across America destinations, and to follow along as the team gives updates on the route home, visit KĀLO Trek online .

About Kymeta

What’s the missing link to connecting billions of people to high-speed mobile access? Antennas. And Kymeta offers the world’s only commercially viable electronically scanning satellite antennas and terminals. Kymeta antennas and terminals deliver high-throughput communications for land, sea and air, making mobile connectivity as available as a view of the sky. Plus, the world’s largest satellite operator, Intelsat, has joined forces with Kymeta to deliver KĀLO™ global access services that combine with Kymeta antennas and terminals to provide revolutionary mobile connectivity. Without Kymeta mTenna™ technology, connecting and staying connected to all those new satellites while on the move will be difficult, if not impossible.

If it moves, Kymeta will keep it connected. Anywhere.

For more information, visit kymetacorp.com and KALO.net .

Contact:

Business Inquiries for Kymeta:
Kymeta Corporation
Lisa Dreher, +1 425-658-8724
Director of Marketing
ldreher@kymetacorp.com
or
Media Inquiries for Kymeta:
The Summit Group
Amy Oliver, +1 801-990-1185
Mobile: +1 801-783-9067
PR/Content Manager
aoliver@summitslc.com

Link:

ClickThru

Social Media:

http://www.facebook.com/KymetaCorp

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye